Enveric Biosciences, Inc. filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock under its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. The company has previously sold an aggregate of $4,483,711.04 through this agreement. Enveric Biosciences, Inc. is a biotechnology company focused on developing novel drug delivery technologies and therapeutics.

Enveric Biosciences, Inc. released an Investor Presentation for the second quarter of 2026. The presentation is intended for use in discussions with investors, analysts, lenders, and potential business partners. Enveric Biosciences, Inc. is a biotechnology company focused on developing drug delivery technologies and itself as a platform for a drug discovery platform.